10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates ...

Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the 4th quarter, according to the company in its most recent filing with the ...